



Pearls from Procurement

What the Clinician Needs to Know-Devices Machine Perfusion

RODNEY JONES

VICE PRESIDENT STRATEGIC PARTNERSHIPS

NORA



Disclosures

NONE RELATED TO THIS TALK

THE NATIONWIDE ORGAN RECOVERY TRANSPORT ALLIANCE
PREVIOUS XVIVO

Overview of organ transplantation process

- ▶ DBD = Donation after Brain Death
 - ▶ The Harvard Medical School's ad hoc committee defined brain death in 1968 using the following criteria
- ▶ DCD = Donation after Circulatory Death
 - ▶ Christiaan Barnard was a South African surgeon who performed the world's first human-to-human heart transplant on December 3, 1967
- ▶ NRP = Normothermic Regional Perfusion
 - ▶ Procedure that uses a machine to circulate blood through organs after a donor's heart has stopped beating.
- ▶ HMP = Hypothermic Machine Perfusion
- ▶ NMP = Normothermic Machine Perfusion
- ▶ HOPE = Hypothermic Oxygenated Machine Perfusion
- ▶ COR = Controlled Oxygenated Rewarming

Traditional Cold Storage vs. Machine HMP & NMP Perfusion

- Cold storage V. machine perfusion
 - Gold Standard; 1960 Collins , UW : Low Na+ High K+ / ice 4°C
 - Gold Standard
 - Safe, Efficacious, Affordable
- Machine perfusion;
 - Expensive, complex, resource intensive

Cold Storage v. Machine Perfusion

Method	Temp	Organ	Merits	Challenges
Cold Static Storage	0-8° c	KI,LI,LU,HT	Low Cost, Simple	Metabolic Accumulation, No Assessment
Hypothermic Machine Perfusion	0-8° c	KI,LI,LU,HT	Provides Oxygen and Metabolic Substrates	No Assessment, Perfusion time limited
Normothermic Machine Perfusion	35-38° c	KI,LI,LU,HT	Provides O2, Substrates, Metabolic Viability, Assessment and Repair	Perfusion Time Limited, Complex, Labor Intensive
Controlled Oxygenated Rewarming	8-20° c	KI,LI,LU	Gradual Warming of Perfusate to mitigate Reperfusion Injury	TBD


Hypothermic Machine Perfusion

- ▶ HMP 0-8°
- ▶ 1968 Belzer performed 1st Kidney concept generating metabolic substrates for the generation of ATP
- ▶ 1990 saw an increase in HMP due to increased demand and use of marginal organs. HMP demonstrated improved outcomes and graft function. (Mainly Kidney Driven)


Indications for Hypothermic Machine Perfusion

- ▶ Prolonged warm Ischemia
- ▶ Uncontrolled DCD
- ▶ Poor and/or incomplete flush during organ recovery
- ▶ High risk and/or marginal donor
- ▶ Prolonged allocation
- ▶ Prolonged transport

Mechanisms of Action with the addition of Oxygen in HMP



The Mitochondrial Electron Transport Chain =



Oxygenated versus standard cold perfusion preservation in kidney transplantation (COMPARE): a randomized, double-blind, paired, phase 3 trial

Lancet 2020 Nov 21, 396 (10263) 1653- 1662

- ▶ 19 European Centers
- ▶ 197 Kidney Pairs randomized, double blinded phase 3 trial
- ▶ 106 pairs transplanted
- ▶ DCD donors >50YO
- ▶ 1KI w/ HMPO, 2nd KI/ HMP alone
- ▶ 11.% Improved Renal Function
- ▶ 73% Fewer graft failures
- ▶ 44% Lower Incidence of acute rejection
- ▶ 31% Reduced incident of severe post transplant complications

FDA Approved Kidney Devices



Normothermic Machine Perfusion

35-38°C

- ▶ Maintains metabolic activity and viability
- ▶ Designed primarily as an assessment tool
 - ▶ Expanded use
- ▶ 2007 Steen et al, first lung after 6 hr EVLP assessment
- ▶ 2008 Cypel et al, 12hr w/ change in protocol
- ▶ 2016 first NMP in Livers
- ▶ 2021 OCS Heart System, indicated for DCD hearts

Challenges for NMP

- ▶ Lack of Standardization
 - ▶ Various protocols
- ▶ Logistical Complexity
 - ▶ Not easily transported, Not approved for commercial transport
- ▶ High Cost
 - ▶ \$50,000-\$100,000
- ▶ Technologically Complex
 - ▶ Requires special knowledge , CCP/ECMO/RRT/Other
- ▶ Perfusion Related Injuries
 - ▶ Mechanical injuries, microvascular damage, shear stress, edema
- ▶ Perfusate Challenges
 - ▶ Mimics blood, nutrients, oxygen carrying capacity

Benefits of NMP

- ▶ Real Time Functional Assessment
- ▶ Improved Marginal Organ Utilization
- ▶ Reduced Ischemia Reperfusion Injury
- ▶ Enhanced Organ Function Post – Transplant
- ▶ Improved Graft Survival
- ▶ Facilitation of Complex Transplants
- ▶ Improved Matching Opportunities


The Goal for NMP

- ▶ Organ Assessment
- ▶ Organ Repair
- ▶ Prevent Ischemia Reperfusion Injury
- ▶ Organ Immuno-modulation
- ▶ Remove metabolic waste
- ▶ Organ regeneration
- ▶ Supply Oxygen and Nutrients

Liver Assessment

- ▶ FMN
- ▶ Transaminase
- ▶ Bile Production / Ph , Glucose, BiCarb
- ▶ Lactate
- ▶ Glucose clarence
- ▶ Coagulation

NMP- Liver



NMP-Lung



Non-Transport, Extensive Evaluation



Transportable , limited evaluation

Heart NMP / HOPE



FDA Approved, Transportable

Donor heart travels 12 hours across Atlantic before use in successful transplant in world first



Clinical Trail , Transportable, 8°C

Alternative Devices Not Perfusion, but preservation

- ▶ No Assessment
- ▶ Maintains constant temperature w/o ice
- ▶ Prolonged safe storage
- ▶ Lower cost than MP devices



Conclusion

- ▶ HMP
 - ▶ Safe, Effective, Improved Outcomes, Affordable, easily transportable, Oxygen compatible, No Assessment
- ▶ NMP
 - ▶ Complex, Effective, Assessment, Improved Outcomes, Expensive, difficult to transport, labor intensive.
- ▶ Face changing coolers
 - ▶ Promising results, safe, affordable, transportable, No Assessment, No Oxygen

Q&A

- ▶ • Open floor for questions and discussion